Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

  • This share is currently suspended. It was suspended at a price of 7.23
  • There is currently no data for TRX

Offer Update

29 Jul 2005 18:04

Torex Retail PLC29 July 2005 Torex Retail plc29 July 2005 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN TOREX RETAIL PLC ___________________________________________________________________________ RECOMMENDED OFFER FOR XN CHECKOUT HOLDINGS PLC Offer Unconditional as to Acceptances As at 1.00 p.m. on 29 July 2005, valid acceptances had been received in respectof 24,777,251 XN Checkout Shares (representing approximately 89.19 per cent ofXN Checkout's issued share capital). Accordingly, the Board of Torex Retail plc("Torex Retail") announces that the offer (the "Offer") made by EvolutionSecurities Limited on behalf of Torex Retail for XN Checkout Holdings PLC ("XNCheckout") has been declared unconditional as to acceptances. The Offer remains conditional upon the admission to trading on AiM of the newTorex Shares issued as consideration under the Offer ("New Torex Shares")becoming effective. Application has therefore been made for the admission of 63,107,579 New TorexShares to trading on AiM and it is expected that these New Torex Shares will beadmitted to trading on AiM and that dealings in those shares will commence on 4August 2005, when it is also expected that the Offer will become whollyunconditional. Save for the holding of Christopher Moore (Chief Executive of Torex Retail andNon-Executive Chairman of XN Checkout) of 2,580,497 XN Checkout Shares, neitherTorex Retail nor any persons deemed to be acting in concert with it for thepurposes of the Offer owned any XN Checkout Shares (or rights over such shares)on 3 June 2005 (being the last dealing day prior to the commencement of theOffer period) nor has Torex Retail nor any person deemed to be acting in concertwith it for the purposes of the Offer acquired or agreed to acquire any XNCheckout Shares (or rights over such shares) during the Offer period other thanby way of acceptances of the Offer. On 10 June 2005, Torex Retail announced that irrevocable undertakings to acceptthe Offer had been received from XN Checkout Shareholders who, in aggregate,have an interest in 10,540,085 XN Checkout Shares. Valid acceptances have beenreceived in respect of 8,500,718 of these XN Checkout Shares (representingapproximately 30.60 per cent of XN Checkout's issued share capital) and theseare included in the total above. In respect of the balance of 2,039,367 XNCheckout Shares, the acceptance form has been received duly signed, but without,as yet, sufficient supporting documentation to treat it as a valid acceptanceand therefore has not been included in the total above. The Offer will remain open until further notice. At least 14 days' notice willbe given before the Offer is closed. Terms defined in the formal Offer document dated 8 July 2005 shall, unless thecontext requires otherwise, have the same meanings in this announcement. EnquiriesTorex Retail Telephone: 01993 230 030Richard Thompson / Nigel Horn Evolution Telephone: 0207 071 4300Tim Worlledge / Jeremy Ellis This announcement is issued by Evolution which is authorised and regulated inthe United Kingdom by the Financial Services Authority. Evolution is actingexclusively for Torex Retail and is acting for no one else in connection withthe Offer and will not be responsible to anyone other than Torex Retail forproviding the protections afforded to customers of Evolution nor for providingadvice in relation to the Offer. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
28th Jun 20217:00 amRNSCompletion of phase 1 of new US facility expansion
23rd Jun 20216:08 pmRNSDirector/PDMR Shareholding
10th Jun 20214:17 pmRNSHolding(s) in Company
3rd Jun 20211:37 pmRNSResult of AGM
11th May 20217:00 amRNSDirector/PDMR Shareholding
10th May 202110:00 amRNSDirector/PDMR Shareholding
5th May 20217:00 amRNSGrant of share options
29th Apr 20214:11 pmRNSHolding(s) in Company
28th Apr 20217:00 amRNSFinal Results and Notice of AGM
20th Apr 20211:07 pmRNSHolding(s) in Company
20th Apr 202112:10 pmRNSHolding(s) in Company
19th Apr 20217:00 amRNSNotice of Results
13th Apr 20217:00 amRNSHolding(s) in Company
1st Apr 20214:40 pmRNSSecond Price Monitoring Extn
1st Apr 20214:36 pmRNSPrice Monitoring Extension
18th Mar 20217:00 amRNSInitial phase of US facility expansion complete
26th Feb 20217:00 amRNSDirectorate Change
19th Feb 20213:52 pmRNSHolding(s) in Company
11th Feb 20217:00 amRNSMove to Electronic Reporting
8th Feb 20217:00 amRNSTrading Update
5th Feb 20214:40 pmRNSSecond Price Monitoring Extn
5th Feb 20214:35 pmRNSPrice Monitoring Extension
21st Jan 20217:00 amRNSAppointment of Chief Financial Officer
6th Jan 20213:58 pmRNSPDMR Dealings
5th Jan 20217:00 amRNSConfirmation of Board appointments
4th Jan 202111:26 amRNSHoldings in Company
24th Dec 202012:56 pmRNSIssue of Equity & Total Voting Rights Replacement
24th Dec 202011:15 amRNSHoldings in Company
23rd Dec 20209:51 amRNSIssue of Equity and Total Voting Rights
4th Dec 20207:00 amRNSBoard Changes
3rd Dec 20204:54 pmRNSHoldings in Company
2nd Dec 20207:00 amRNSFirst delivery of OrthoPure® XT
27th Nov 20209:09 amRNSHoldings in Company
26th Nov 20204:02 pmRNSHoldings in Company
17th Nov 20207:00 amRNSAppointment of CEO
6th Nov 20207:00 amRNSHoldings in Company
29th Oct 20207:00 amRNSHoldings in Company
29th Oct 20207:00 amRNSChange of Registered Office
26th Oct 20204:50 pmRNSHoldings in Company
7th Oct 20201:50 pmEQSHardman & Co Research: Tissue Regenix (TRX): Funded through to profitability
28th Sep 202012:24 pmRNSHoldings in Company
16th Sep 20207:42 amRNSHoldings in Company
15th Sep 20204:40 pmRNSSecond Price Monitoring Extn
15th Sep 20204:35 pmRNSPrice Monitoring Extension
14th Sep 20205:33 pmRNSHoldings in Company
2nd Sep 20207:00 amRNSUnaudited Interim Results
27th Aug 20207:00 amRNSNotice of Interim Results & Investor Presentation
24th Aug 20207:00 amRNSUK distribution partner for OrthoPure® XT
18th Aug 202011:27 amRNSHoldings in Company
17th Aug 20207:00 amRNSRelocation of UK office and manufacturing facility

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.